Moderna, Merck advance cancer vaccine into late-stage test
Moderna, Merck advance cancer vaccine into late-stage test Moderna and Merck & Co. are pushing ahead with the industry’s most-advanced experimental cancer vaccine, announcing Wednesday they’ve begun enrolling patients in a Phase 3 trial aimed at preventing the return of melanoma after surgery. Initiation of the trial marks another milestone